Sign In
Buy OYST
$11.17
+0 (+0%)
At Close: Mar 29, 2023
Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 (varenicline) Nasal Spray
04:42pm, Tuesday, 29'th Jun 2021
PRINCETON, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced information regarding a key supply chain insight for OC-01 (varenicline) nasal spray follow
Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit
04:01pm, Monday, 21'st Jun 2021
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of f
Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases
07:00am, Thursday, 10'th Jun 2021
PRINCETON, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of f
PRINCETON, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of f
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q1 2021 Results - Earnings Call Transcript
02:59pm, Sunday, 09'th May 2021
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q1 2021 Results - Earnings Call Transcript
New Strong Sell Stocks for May 6th
10:31am, Thursday, 06'th May 2021
OYST, CDAY, GWPH, HRTG, and NATI have been added to the Zacks Rank #5 (Strong Sell) List on May 6, 2021
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fi
Oyster Point Pharma Announces New Appointment to Board of Directors
06:00am, Monday, 05'th Apr 2021
George Eliades joins the Board of Directors George Eliades joins the Board of Directors
PRINCETON, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2020 Results - Earnings Call Transcript
08:58pm, Thursday, 18'th Feb 2021
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2020 Results - Earnings Call Transcript
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
09:14am, Friday, 12'th Feb 2021
Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET
Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 29'th Dec 2020
PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of f
The NDA submission is based on efficacy and safety results from a comprehensive clinical trial program conducted in patients with a broad range of dry eye disease. The NDA submission is based on effic
Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers
07:00am, Monday, 07'th Dec 2020
Industry veterans in ophthalmology will lead and expand the company's R&D and clinical efforts Industry veterans in ophthalmology will lead and expand the company's R&D and clinical efforts
